<DOC>
	<DOCNO>NCT00890565</DOCNO>
	<brief_summary>This study aim evaluate electrocardiogram ( ECG ) effect Sancuso® compare placebo moxifloxacin healthy subject .</brief_summary>
	<brief_title>Safety Study Electrocardiogram ( ECG ) Effects Sancuso® ( Granisetron TDS )</brief_title>
	<detailed_description>Granisetron well test establish 5-HT3 receptor antagonist use oral intravenous ( IV ) form . A transdermal form granisetron ( Sancuso® ) approve United States ( US ) Food Drug Administration ( FDA ) September 2008 . Many 5-HT3 antagonist develop approve adoption International Conference Harmonisation ( ICH ) E14 standard QTc cardiac testing . The association non-cardiac medicinal product potential prolong QT interval induce torsades des pointes ( TdP ) significant implication future development medicinal product .</detailed_description>
	<mesh_term>Granisetron</mesh_term>
	<mesh_term>Moxifloxacin</mesh_term>
	<mesh_term>Fluoroquinolones</mesh_term>
	<mesh_term>Norgestimate , ethinyl estradiol drug combination</mesh_term>
	<criteria>Healthy male female subject Aged 18 50 year , inclusive , screen BMI 18.0 32.0 kg/m² , inclusive History drug abuse Known hypersensitivity granisetron , moxifloxacin , related compound , ciprofloxacin levofloxacin Sustained supine systolic blood pressure &gt; 140 mmHg &lt; 100 mmHg diastolic blood pressure &gt; 95 mmHg Screening baseline Pulse rate rest &lt; 45 bpm &gt; 100 bpm Abnormal Screening ECG indicate second third degree AV block , one following : QRS &gt; 120 millisecond ( m ) ; QTcF &gt; 430 ( male ) 450 ( female ) ms ; PR interval &gt; 240 m ; rhythm , sinus rhythm , interpret clinically significant Investigator Known history longQT syndrome , angina , myocardial ischemia infarction , congestive heart failure , myocarditis , chest pain dyspnea exertion Electrolyte disturbance ( uncorrected hypokalemia/hyperkalemia , hypomagnesemia , hypocalcemia , hypophosphatemia ) , idiopathic cardiomyopathy , unexplained syncope , hypertrophic cardiomyopathy , sudden unexplained death young age ( &lt; 40 year ) firstdegree relative . Has use medication consume food contraindicate protocol .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>October 2009</verification_date>
	<keyword>Electrocardiogram</keyword>
	<keyword>Effect electrocardiogram</keyword>
	<keyword>Granisetron</keyword>
	<keyword>Moxifloxacin</keyword>
	<keyword>Pharmacokinetic profile</keyword>
	<keyword>Sancuso® patch</keyword>
	<keyword>Transdermal</keyword>
</DOC>